Fresenius Medical Care: Doctor Payments and an Internal Cover-Up

Fresenius Medical Care agreed to pay $147 million to the Securities and Exchange Commission in the Fresenius FCPA case over doctor payments, disguised commissions and false accounting. Under its criminal non-prosecution agreement, Fresenius admitted earning more than $140 million in profits from corrupt schemes, according to the Justice Department’s announcement.

Employees’ checks became cash for government doctors, a charity became a route to hospital orders, and managers altered records after an investigation began. We see a civil payment on the scale of the profits from buying public officials. For someone inside sales, finance or a distributor, this case connects the payment on the books to the decision it was buying.

The German company supplied dialysis products and services for people with chronic kidney failure. At the time of the SEC’s March 29, 2019 order, it operated in more than 150 countries and had shares trading on the New York Stock Exchange. Its business reached public hospitals through subsidiaries, distributors and joint ventures whose accounts fed into the parent’s financial statements.

A 2022 Journal of Forensic and Investigative Accounting case study of Fresenius explains the commercial setting: the company both provided dialysis treatment and manufactured and distributed the products used in it. The study places healthcare corruption across purchasing, payment systems, supply chains and care delivery. Public hospital doctors and administrators could influence which machine a hospital bought, which clinic received patients, or when a supplier got paid. Those were different opportunities to buy influence inside the same business.

Employee Checks Became Cash for Government Doctors

Under its non-prosecution agreement, Fresenius admitted using employee checks to generate cash for payments to Saudi government doctors and others, as the Justice Department’s account of the admissions explains. Employees cashed checks payable to themselves and returned the money to the general manager of Saudi Advanced Renal Services, the company’s distributor and agent. That manager arranged its delivery to the recipients.

The SEC order put the cash generated through this scheme at approximately $1.77 million. It described bags of cash sometimes kept in a safe and transactions falsely recorded as project marketing expenses and collection commissions. These entries reached Fresenius’s consolidated accounts. The employee named on the check was a step in the payment route, while the ledger supplied a different explanation for the money.

In the same non-prosecution agreement, the company also admitted sham consulting and commission arrangements for services never performed. In one collection arrangement described by the SEC, a Ministry of Health employee’s relative received over $200,000 for work salaried staff had already done, more than those employees’ combined salaries. Fresenius won the tender. We see a payment for influence dressed as payment for work already done. Paid twice, for different reasons.

The travel bills carried another misleading description. In the facts admitted under its non-prosecution agreement, Fresenius described six hotel nights for a Saudi doctor and his wife recorded as congress-related despite no evidence of participation. That gap connects the finance records to what sales staff know about the travel.

Fresenius Charitable Foundation Payments and Official Influence

The charitable foundation payments in the Fresenius FCPA case connected a donation to an official’s influence over hospital orders. Under its non-prosecution agreement, Fresenius admitted making payments to a government charity to obtain business, and the SEC described a charity chief with influence over Ministry of Health tenders. The general manager’s email made the connection explicit:

That is what makes the charitable donation part of the sales story. The SEC also described a different doctor who sat on a government-founded charity’s board and received consulting payments through entities he owned. Payments continued after the contracts expired, with no evidence of services. The recipient’s public role, control of the beneficiary and influence over orders explain what a donation or consulting entry alone leaves out.

Customs Payments Hidden in Handling Charges

The SEC order also described at least $31,000 in improper payments to Saudi customs officials through a third-party agent to avoid or reduce penalties and fees. The agent’s invoices called the payments handling charges or miscellaneous expenses. Another $1.76 million paid to the agent lacked supporting documentation of services. For someone who knows the shipments, the agent’s invoice and the reason a customs charge disappeared belong to the same story.

A Moroccan Hospital Commission Disguised as an Employee Bonus

The Morocco scheme moved a hospital commission through an employee’s pay. The SEC found that senior Fresenius personnel arranged a sham marketing agreement with the chief nephrologist at two state-owned military hospitals. To produce $123,000 in cash for the official, they paid a fake bonus to a West Africa manager with a German bank account and backdated the bonus paperwork and employment-contract amendment.

The manager traveled to Germany with the official’s brother, withdrew the money and handed it to him for the official. Less than a month later, Fresenius Morocco entered a contract to build and supply a dialysis center at Agadir Military Hospital.

The personnel file was therefore part of the payment evidence. A backdated bonus, the employee’s bank account and the hospital contract connected people in different countries to the same business decision. An insider who knew why the bonus had appeared could explain something the payroll description concealed.

Distributor Margins Hid the Cost of Bribes

In West Africa, the SEC described a scheme that changed form while continuing to pay public hospital doctors and administrators. In Gabon, consulting agreements promised hospital executives a kickback for each dialysis kit sold. A third-party supplier later carried the payments through sham service fees, and then became a purported distributor.

That change mattered to the accounts. Instead of showing the supplier’s fee as an expense, Fresenius sold products to it at a steep discount, leaving a distributor margin that funded payments to doctors. Fresenius still paid to deliver the goods to customers. When a sales manager questioned the lost revenue, the regional finance director explained that the distributor was absorbing the phony commissions.

The SEC found that shifting the payments made Fresenius’s recorded expenses look lower. We see the same commercial cost changing its accounting address: the bribe disappears from the expense line because the supplier has surrendered revenue to the intermediary. An insider’s knowledge of the customer price and the distributor’s actual work can make that change visible.

Free Shares and Storage Nobody Supplied

In Angola, the SEC found that Fresenius transferred a stake in its local business to government-connected nephrologists without payment for the shares. A distributor owned by a military official’s sons also received money for storage it never provided. Fresenius already had a warehouse arrangement for the same service at a lower cost.

The response to an internal payment freeze showed how the relationship could continue through another transaction. According to the order, Fresenius gave that distributor an exclusive product line and a major customer, creating a substantial resale margin during the freeze. The ownership documents, warehouse lease and new distribution arrangement belonged to the same inquiry: who benefited from the public hospital business, and how did the money keep reaching them?

Turkey supplied another version of the equity route. The SEC described joint ventures in which publicly employed doctors received shares without contributing capital, in exchange for directing patients to Fresenius clinics. Some shares were held in other people’s names. Later buyouts included payments linked to patient enrollment, turning the referrals into the value of the doctor’s stake.

The forensic-accounting case study identifies joint ventures as a way these payments were disguised. That matters to someone who works on clinic acquisitions or valuations: the promised referrals, unpaid share subscription and eventual buyout price can tell the story that a consulting invoice would tell elsewhere.

Spanish Doctors Helped Shape the Tender

In Spain, the SEC described payments and benefits to publicly employed doctors who provided advance tender information or helped influence hospital purchasing. For a Valencia hospital tender, Fresenius supplied a doctor with draft technical specifications, a scoring method and proposed scores. The doctor agreed to some proposals through personal email, and Fresenius won the contract.

The order tied the relationship to consulting payments, a donation to the hospital foundation for the doctor’s training programs, travel and gifts. For someone inside public procurement, the revealing document may be the draft specification before competing suppliers ever see it. We see the unfairness in that sequence: a supplier helped write the test it wanted to win.

Other Spanish arrangements followed patients into clinics. The SEC found that Fresenius acquired a clinic owned by publicly employed doctors, then paid them 5% of subsequent sales and later leased space from them. Consulting agreements with doctor-owned businesses supplied additional compensation. Acquisition payments, rent and consulting fees gave the relationship several places to appear in the accounts.

Personal email and consulting fees also appear in the criminal indictment described in the Justice Department’s Balt announcement. Prosecutors accused an executive and a consultant of routing payments to a French public-hospital physician to secure medical-device purchases. They alleged sham consulting agreements, fake invoices and personal email.

Treatment Counts Became Payment Formulas

In China, the SEC found that Fresenius’s Nephrocare clinic business used bonuses partly based on treatments and new patients. Emails suggested that the payments aimed to influence procurement. Accounting entries described the payments as center marketing fees, and a manager cautioned a colleague against calling them bonuses because of compliance concerns.

The order also described expense accruals that could not adequately be tied to particular payments. That is a concrete issue for finance and accounting staff: the treatment count, the calculation and the eventual recipient may sit in different records.

Mexico put that payment formula into a contract after the business had been won. The SEC described retroactive per-treatment commissions to a distributor after a state-run social insurance tender, with internal auditors identifying improper commissions intended partly for agency officials.

A Different Vendor, the Same Doctors

In Serbia, the SEC described doctors receiving Fresenius payments while serving on public purchasing commissions from which the company sought business. Conference travel also included extra accommodation and nonbusiness side trips. After compliance prohibited payments through a Serbian agent, an executive approved payments through a transport vendor that paid the doctors instead.

The SEC also described Fresenius giving a Serbian doctor’s distributorship cash and free dialysis machines, which the distributor resold to Fresenius to extend a tender and avoid import taxes. The purchase records therefore connected the company to equipment it had already given away.

In Bosnia, the order described a government doctor’s tender-linked consulting agreement moving into his wife’s name after he became mayor. The changed payee kept the same influential household in the payment route.

The Internal Cover-Up Left Another Trail

Fresenius’s internal cover-up reached beyond the original accounting entries. In the facts admitted under its non-prosecution agreement, the Saudi distributor manager directed altered and destroyed documents, fictitious records and false statements after the internal investigation began. The SEC separately described employees creating fake accounting support for a $100,000 cash transaction connected to a major Ministry of Health bid. Discovery of that payment led Fresenius to withdraw from the tender.

Warnings had already reached headquarters. The SEC order described a senior Saudi finance officer reporting false invoices and unsupported marketing and travel expenses to German management, then escalating to the controller and head of Internal Audit. The conduct continued after those reports. The books and records problem included who knew the descriptions were false and what management did with that knowledge.

Morocco supplied another direct connection between an investigation and missing records. The SEC described a whistleblower email and later complaints about payments at military hospitals, followed by managers deleting files and destroying records after receiving preservation notices. In West Africa, its account went further:

The forensic-accounting study’s conclusion fits those changes. It describes employees and managers circumventing controls and continuing payments despite flagged transactions and company policies. We look at the warning, the payment that followed it and the replacement explanation together. Someone who saw the explanation being rewritten may understand the concealment more clearly than anyone reading the final invoice.

What the Fresenius Resolution Covered

The Securities and Exchange Commission’s Foreign Corrupt Practices Act order required Fresenius to surrender gains from the misconduct and pay interest. Its order found anti-bribery violations in Saudi Arabia, Angola and West Africa, with false accounting and inadequate controls across the wider set of countries it described. The separate criminal non-prosecution agreement carried company admissions about payments and accounting failures.

The Justice Department described misconduct in 13 countries, with admitted conduct between 2007 and 2016. Its announcement identified the FBI’s International Corruption Squad in New York and its Boston Field Office as the investigators.

The forensic-accounting study traces the internal investigation to a whistleblower’s report about Latin America in 2012. The Justice Department credited Fresenius with self-disclosing, but said responses to some government requests were late or incomplete. The company brought the matter forward, then failed to supply complete, timely answers.

The SEC whistleblower program can pay eligible whistleblowers 10% to 30% of the money collected in qualifying cases. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers under that separate law. Our whistleblower experts know which program fits what you hold.

You Know What the Payment Was Buying

If you saw employee checks turned into cash, a doctor’s commission hidden in a distributor margin, or customs payments buried in a customs agent’s charges, talk with our whistleblower experts about the payments you saw. We build the case with you, connect your knowledge to the business decisions and bring in FCPA whistleblower lawyers who understand health care purchasing, customs payments and false accounting. We stay beside you through the process, working to build your strongest whistleblower case.